Paris-based biotechnology company Abivax, which develops treatments for chronic inflammatory diseases, saw its shares jump 36% on Tuesday after releasing new data on its lead drug candidate, obefazimod.
The latest results from the maintenance phase of its Phase 3 ABTECT trial showed the experimental oral treatment provided“clinically meaningful improvements” for adults with moderate to severe ulcerative colitis, including patients whose disease had previously failed to respond to treatment.
